Top

Published in:

01-04-2021 | Coronavirus

Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19

Authors: Xin Wang, Kamal Kant Sahu, Jan Cerny

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2021

Abstract

Coronavirus disease-2019 (COVID-19) is a rapidly evolving health crisis caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 is a novel disease entity and we are in a learning phase with regards to the pathogenesis, disease manifestations, and therapeutics. In addition to the primary lung injury, many patients especially the ones with moderate to severe COVID-19 display evidence of endothelial damage, complement activation, which leads to a pro-coagulable state. While there are still missing links in our understanding, the interplay of endothelium, complement system activation, and immune response to the SARS-CoV-2 virus is a surprisingly major factor in COVID-19 pathogenesis. One could envision COVID-19 becoming a novel hematological syndrome. This review is to discuss the available literature with regards to the involvement of the complement system, and coagulation cascade and their interaction with endothelium.

Sahu KK, Kumar R (2020) Current perspective on pandemic of COVID-19 in the United States. J Family Med Prim Care 9(4):1784–1791PubMedPubMedCentral

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, Chine: a descriptive study. Lancet 395:507–513PubMedPubMedCentral

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323(11):1061–1069PubMedPubMedCentral

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan China: a retrospective cohort study. Lancet 395:1054–1062PubMedPubMedCentral

Helms J, Tacquar C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al (2020) High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46:1089–1098PubMedPubMedCentral

Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA et al (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14888CrossRefPubMedPubMedCentral

Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X et al (2020) High risk of thrombosis in patients in severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 4:1–10

Sahu KK, Siddiqui AD (2020) From hematologist’s desk: the effect of COVID-19 on the blood system. Am J Hematol 95(8):E213–E215PubMed

Sahu KK, Law AD, Kumar G, Dhir V, Naseem S, Nada R, Varma SC, Malhotra P (2016) Unusual cause of tophi with renal thrombotic microangiopathy. Indian J Hematol Blood Transfus 32(Suppl 1):100–103PubMed

10.

Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood 135(23):2033–2040PubMed

11.

Butenas S, Orfeo T, Mann KG (2009) Tissue factor in coagulation: Which? Where? When? Arterioscler Thromb Vac Biol 29(12):1989–1996

12.

Foley JH, Conway EM (2016) Cross talk pathways between coagulation and inflammation. Circ Res 118:1392–1408PubMed

13.

Taylor FB, Toh CH, Hoots WK, Wada H, Levi M et al (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327–1330PubMed

14.

Iba T, Levy JH, Warkentin TE, Thachil J, van der Poll T, Levi M et al (2019) Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Heemost 17:1989–1994

15.

Levi M, Thachil J, Iba T, Levy JH (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 7(6):e438–e440PubMedPubMedCentral

16.

Taylor FB, Toh CH, Hoots WK, Wada H, Levi M (2001) Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86(5):1327–1330PubMed

17.

Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 395:497–506PubMed

18.

Lin L, Lu L, Cao W, Li T (2020) Hypothesis for potential pathogenesis of SARS-CoV-2 infection—a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 9(1):727–732PubMedPubMedCentral

19.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet Lond Engl 395(10234):1417–1418

20.

Monteil V, Kwon H, Prado P, Hagelkrüys A, Wimmer RA, Stahl M et al (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 181(4):905–913PubMedPubMedCentral

21.

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 383:120–128PubMedPubMedCentral

22.

Bonetti PO, Lerman LO, Lerman A (2003) Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23(2):168–175PubMed

23.

Ghirga G (2020) Pre-existing endothelial dysfunction:*m a unifying hypothesis for the burden of severe SARS-CoV-2. BMJ 368:m627

24.

Mishra AK, Lal A, Sahu KK, Sargent J (2020) Cardiovascular factors predicting poor outcome in COVID—19 patients. Cardiovasc Pathol 49:107246PubMedPubMedCentral

25.

Campbell CM, Kahwash R (2020) Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis. Circulation 141:1739–1741PubMed

26.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet Lond Engl 395(10223):497–506

27.

Mishra AK, Sahu KK, Lal A, Sargent J (2020) Patterns of heart Injury in COVID-19 and relation to outcome. J Med Virol. https://doi.org/10.1002/jmv.25847CrossRefPubMedPubMedCentral

28.

Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M et al (2020) Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol. https://doi.org/10.1111/bjh.16457CrossRefPubMedPubMedCentral

29.

Dvorak CC, Higham C, Shimano KA (2019) Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management. Front Pediatr. https://doi.org/10.3389/fped.2019.00133CrossRefPubMedPubMedCentral

30.

Haines HL, Laskin BL, Goebel J, Davies SM, Yin HJ, Lawrence J et al (2011) Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 17:1512–1519PubMed

31.

Martinelli N, Montagnana M, Pizzolo F et al (2020) A relative ADAMTS13 deficiency supports the presence of microangiopathy in COVID-19. Thromb Res 193:170–172PubMedPubMedCentral

32.

Rambaldi A, Gritti G, Mico MC et al (2020) Endothelial injury and thrombotic microagiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunology. https://doi.org/10.1016/j.imbio.2020.152001CrossRef

33.

Rovina N, Akinosoglou K, Eugen-Olsen J et al (2020) Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care 24:187PubMedPubMedCentral

34.

Alberts B, Johnson A, Lewis J et al (2002) Molecular biology of the cell, 4th edn. Garland Science, New York

35.

Nasab MG, Saghazadeh A, Rezaei N (2020) SARS-CoV-2-A tough opponent for the immune system. Arch Med Res. https://doi.org/10.1016/j.arcmed.2020.05.020CrossRefPubMedPubMedCentral

36.

Sahu KK, Mishra AK, Lal A (2020) COIVD-19 disease: tackling a pandemic in 21st century. QJM 113(7):519–520PubMed

37.

Noris M, Benigni A, Remuzzi G (2020) The case of Complement activation in COVID-19 multiorgan impact. Kidney Int. https://doi.org/10.1016/j.kint.2020.05.013CrossRefPubMedPubMedCentral

38.

Lal A, Mishra AK, Sahu KK (2020) CT chest findings in coronavirus disease-19 (COVID-19). J Formos Med Assoc 119(5):1000–1001PubMedPubMedCentral

39.

Jiang Y, Zhao G, Song N, Li P, Chen Y, Guo Y et al (2018) Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect 7(1):77PubMedPubMedCentral

40.

Gralinski LE, Sheahan TP, Morrison TE, Menachery VD, Jensen K, Leist SR et al (2018) Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9(5):e01753PubMedPubMedCentral

41.

Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J et al (2020) Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 220:1–13PubMedPubMedCentral

42.

Lam LM, Murphy SJ, Kuri-Cervantes L, Weisman AR, Ittner CAG, Reilly JP et al (2020) Erythrocytes reveal complement activation in patients with COVID-19. MedRxiv Prepr Serv Health Sci

43.

Gao T, Hu M, Zhang X, Li H, Zhu L, Liu H et al (2020) Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. Infect Dis. https://doi.org/10.1101/2020.03.29.20041962CrossRef

44.

Lopez C, Kim J, Pandey A, Huang T, DeLoughery TG (2020) Simultaneous onset of COVID-19 and autoimmune haemolytic anaemia. Br J Haematol 190:31–32PubMed

45.

Hamad H, Sahu KK, Dunn S, Milla L, Caffery A, Islam N (2020) Rifampin Induced thrombotic thrombocytopenic purpura. Indian J Hematol Blood Transfus. https://doi.org/10.1007/s12288-019-01249-9CrossRefPubMedPubMedCentral

46.

Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J et al (2014) Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood 124(4):645–653PubMedPubMedCentral

47.

Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W et al (2020) Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38PubMed

48.

Ramlall V, Thangaraj P, Meydan C et al (2020) Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. https://doi.org/10.1038/s41591-020-1021-2CrossRefPubMedPubMedCentral

49.

Totura AL, Whitmore A, Agnihothram S, Schäfer A, Katze MG, Heise MT et al (2015) Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio 6:e00638-15PubMedPubMedCentral

50.

Yang Z, Stratton C, Francis PJ, Kleinman ME, Tan PL, Gibbs D, Tong Z, Chen H, Constantine R, Yang X, Chen Y (2008) Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med. https://doi.org/10.1056/nejmoa0802437CrossRefPubMedPubMedCentral

51.

Hajishengallis G, Lambris JD (2016) More than complementing Tolls: complement-Toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol Rev 274(1):233–244PubMedPubMedCentral

52.

Sahu KK, Jindal V, Siddiqui AD, Cerny J, Gerber JM (2020) Convalescent plasma therapy: a passive therapy for an aggressive COVID-19. J Med Virol. https://doi.org/10.1002/jmv.26047CrossRefPubMedPubMedCentral

53.

Sahu KK, Mishra AK, Martin K, Chastain I (2020) COVID-19 and clinical mimics. Correct diagnosis is the key to appropriate therapy. Monaldi Arch Chest Dis Arch Monaldi Mal Torace 90(2):1296

54.

Fu B, Xu X, Wei H (2020) Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med 18(1):164PubMedPubMedCentral

55.

Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC et al (2020) Remdesivir for the treatment of covid-19—preliminary report. N Engl J Med 383:992–994

56.

Diurno F, Numis FG, Porta G, Cirillo F, Maddaluno S, Ragozzino A et al (2020) Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci 24(7):4040–4047PubMed

57.

Risitano AM, Mastellos DC, Huber-Lang M, Yancopoulou D, Garlanda C, Ciceri F et al (2020) Complement as a target in COVID-19? Nat Rev Immunol 20(6):343–344PubMed

58.

Mastellos DC, Ricklin D, Lambris JD (2019) Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 18(9):707–729PubMedPubMedCentral

59.

Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X et al (2020) COVID-19 infection: the perspectives on immune responses. Cell Death Differ 27:1451–1454PubMedPubMedCentral

60.

Mastaglio S, Ruggeri A, Risitano AM, Angelillo P, Yancopoulou D, Mastellos DC et al (2020) The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol Orlando Fla 215:108450

61.

Hajishengallis G, Lambris JD (2016) More than complementing Tolls: Complement-toll-like receptor synergy and crosstalk in innate immunity and inflammation. Immunol Rev 271(1):233–244

62.

RECOVERY Collaborative Group (2020) Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. https://doi.org/10.1056/NEJMoa2021436CrossRef

Title: Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19
Authors: Xin Wang
Kamal Kant Sahu
Jan Cerny
Publication date: 01-04-2021
Publisher: Springer US
Keywords: Coronavirus
SARS-CoV-2
Thrombotic Microangiopathy
COVID-19
Published in: Journal of Thrombosis and Thrombolysis / Issue 3/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02297-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2021

Rescue catheter-based therapies for the treatment of acute massive pulmonary embolism after unsuccessful systemic thrombolysis

Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review

Characteristics and risk factors of deep vein thrombosis in hemiplegic, healthy and bilateral limbs of hemiplegic patients: a 10-year retrospective study

Direct oral anticoagulants are effective and safe in the treatment of venous thromboembolism and atrial fibrillation in morbidly obese patients

Clinical outcomes after percutaneous coronary intervention for early versus late and very late stent thrombosis: a systematic review and meta-analysis

Stress hyperglycemia is predictive of worse outcome in patients with acute ischemic stroke undergoing intravenous thrombolysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page